FMS-like tyrosine kinase 3 (FLT3) enzyme overexpression and mutations are the most
common molecular abnormalities associated with acute myeloid leukemia (AML). In …

FLT3 and PDGFR tyrosine kinases are important targets for therapy of different types of
leukemia. Several FLT3/PDGFR inhibitors are currently under clinical investigation for …

OBJECTIVE: Activating mutations in FLT3 are known to be a frequent transforming event in
acute myeloid leukemia. Small molecule–inhibitor therapy targeting the FLT3 kinase is …

An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which
is expressed in a subpopulation of patients with acute myelocyic leukemia (AML) and is …

FLT3 (fms-like tyrosine kinase 3) is constitutively activated in about 30% of patients with
acute myeloid leukemia (AML) and represents a disease-specific molecular marker …

The FMS-like tyrosine kinase 3 (FLT3) gene encodes a class III receptor tyrosine kinase that
is expressed in hematopoietic stem cells. The mutations of FLT3 gene found in 30% of acute …

Purpose: Fms-like tyrosine kinase 3 (FLT3) encodes a receptor tyrosine kinase (RTK) for
which activating mutations have been identified in a proportion of acute myelogenous …

Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with
FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance …

Abstract Abstract 764 Background: Activating mutations in FLT3 are detected in
approximately 30% of adult acute myeloid leukemia (AML) cases, most commonly involving …

Background: FLT3 is a member of receptor tyrosine kinase III family, mainly expressed in
hematopoietic cells. The aberrant expression and function of FLT3 are strongly related to …